Ophthalmology Times

03/07/2026

VSP Vision Care has released findings from its third annual Workplace Vision Health Report, indicating that US desk workers average nearly 100 hours of screen time per week, with work accounting for a significant share. On weekdays, desk workers report spending 93% of their waking hours looking at screens. According to a news release, 71% say they experience performance impacts due to screen-related visual discomfort, equating to nearly one full workday of lost productivity each week.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

03/06/2026

Ophthalmic drug shortages comprise approximately 15% of all active drug shortages in the US, according to a retrospective analysis of nationally representative data from the University of Utah.

Investigators led by Ian F. Pitha, MD, PhD, an ophthalmologist at the John A. Moran Eye Center, found that not only do ophthalmic drugs constitute a significant rate of the drug shortages reported in the US since 2001—but their shortages generally last nearly a month longer than average.

University of Utah data show US ophthalmic drug and eye drop shortages last longer and occur more often, affecting local and systemic medications equally.

03/05/2026

Maria Berrocal, MD, related the highlights of a case-based roundtable that convened at the recent EnVision Summit in Pio Grande, Puerto Rico. She is an associate professor at the University of Puerto Rico and CEO of Doctors Berrocal and Associates, San Juan, Puerto Rico.

The participants discussed topics relevant to clinical practice that included the roles of vascular endothelial growth factor (VEGF), angiopoietin-2 (ANG2), and inflammatory cytokines in treating diabetic macular edema (DME); the most challenging patient profiles; and the impact of dual inhibition of ANG2 and VEGF-A.

Cases highlight faricimab’s dual VEGF/ANG2 action for severe diabetic macular edema—faster drying, better vision, longer intervals.

03/05/2026

Geographic atrophy (GA), the end-stage of age-related macular degeneration (AMD), recently became treatable. Murtaza Adam, MD, director of clinical research, Colorado Retina, Denver hosted a roundtable discussion at the EnVision Summit in Puerto Rico in which the intricacies of three patients with GA were discussed.

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.

03/04/2026

Ocugen has completed enrollment in liMeliGhT, its phase 3 clinical trial of OCU400 for the treatment of retinitis pigmentosa (RP). The company describes liMeliGHT as a 1-year clinical trial that will support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027.

The company describes liMeliGhT as a 1-year clinical trial that will support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027.

03/03/2026

EyePoint has dosed the first patient in its phase 3 trials COMO and CAPRI evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). DURAVYU is an investigational sustained delivery therapy delivering vorolanib, a selective tyrosine kinase inhibitor (TKI), described by the company to “bring a novel, multi-mechanism of action inhibiting VEGF-mediated vascular permeability, PDGF, and IL-6-mediated inflammation to the potential treatment of DME.”

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

03/02/2026

March is Workplace Eye Awareness Month. The guidelines associated with eye safety in the workplace do not just apply to the general public but to eye care clinicians as well.

In construction and manufacturing industries, for example, in which workers might be exposed to high risks of injuries, compliance with American National Standards Institute (ANSI) standards for personal eye and face protection and enforced by the Occupational Safety and Health Administration is a must. However, healthcare professionals face just as many, if not more, eye hazards daily.

The American Academy of Ophthalmology (AAO) states that 90% of eye injuries can be avoided by wearing appropriate, ANSI-approved eye protection.

Healthcare staff face splashes, aerosols, chemicals and lasers daily; ANSI-rated eye protection and better compliance prevent most workplace injuries.

03/02/2026

In this latest episode of the Ophthalmology Times® “Beyond The Walls” podcast, host Deborah Ristvedt, DO, of Vance Thompson Vision, sits down with William B. Trattler, MD, to explore the experiences, influences, and philosophies that have shaped his career in ophthalmology. The discussion covers early inspirations, approaches to teaching, mentorship initiatives, clinical collaboration, and the evolving role of technology in patient care. Trattler is a refractive, corneal and cataract eye surgeon at the Center For Excellence In Eye Care in Miami, Florida.

Host Deborah Ristvedt, DO, welcomes Trattler to discuss how early inspirations, mentorship, collaboration, and a philosophy of simplifying complex concepts have shaped his ophthalmology career.

03/01/2026

Toric intraocular lens (IOL) implantation in patients aged 3-8 years with congenital cataracts and corneal astigmatism ≥2.0 D provided superior long-term visual outcomes and reduced amblyopia rates versus non-toric monofocal IOL implantation

A recent nonrandomized trial has demonstrated toric IOLs’ efficacy in providing long-term visual outcomes, reducing amblyopia compared to non-toric lenses.

02/28/2026

Learn why Xiidra® could be a preferred treatment choice for symptomatic DED with inflammation. See a leading expert discussing a case study.1 https://hubs.li/Q0453MMG0

See full Prescribing Information: https://hubs.li/Q0453HrT0

Reference(s): 1. Data on file Bausch & Lomb Inc.

02/28/2026

The US Food and Drug Administration (FDA) has accepted for a review a supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% (Ryzumvi) for the treatment of presbyopia from Opus Genetics.

The FDA has assigned a PDUFA goal date of October 17, 2026.

02/28/2026

Check out the latest issue of Ophthalmology Times! Read about a blueprint for early detection and ocular surface optimization in glaucoma. Also, learn about the art and science of presbyopia correction, how global trial equity is changing US eye research, and building a dry eye clinic around intense pulsed light.

Read the full issue now: https://hubs.li/Q0450Q1y0